As previously reported, Raymond James analyst Danielle Brill upgraded Disc Medicine (IRON) to Strong Buy from Outperform with a price target of ...

Disc is planning to develop bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic ...

References used to create this graphic: Kakoullis, Loukas, Stylianos Louppides, Eleni Papachristodoulou, and George Panos. “Porphyrias and Photosensitivity: Pathophysiology for the Clinician.” ...

Jefferies issued a $89 price target on Disc Medicine (IRON), estimating a multi-billion dollar peak adjusted revenue opportunity for the company across erythropoietic porphyrias, myelofibrosis ...

Jefferies initiated its coverage of hematology-focused biotech Disc Medicine (NASDAQ:IRON) with a buy recommendation on Wednesday, citing the potential of its lead candidate, bitopertin, targeted at a ...

Erythropoietic protoporphyria (EPP) is one of several rare inherited disorders called porphyrias. Patients with EPP have mutations in one or more genes that cause them to have decreased activity of an ...